Ion Torrent™ Webinars

Learn Why Labs of All Sizes Are Doing Exome Sequencing Using Ion AmpliSeq™ Exome Solution

Jeremy Stuart will present how he is using the Ion AmpliSeq™ Exome solution to identify disease-causing variants in his research. Dr. Stuart currently serves as the VP at Selah Genomics. After receiving his doctorate from Harvard University in Genetics & Complex Diseases, he became one of the founding R&D members of the SOLiD NGS platform, gaining extensive experience with NGS technologies and applications while co-authoring two patents in this space. He has collaborated closely with sites such as the Broad Institute and Memorial Sloan Kettering to integrate NGS methodologies into their research. In October 2012, Dr. Stuart was appointed as adjunct faculty at the University of South Carolina in the dept. of Biological Sciences.

Revolutionizing Clinical Research with Ion AmpliSeq™ Exome Solution

Vince Funari will present how he is using the Ion AmpliSeq™ Exome solution to identify disease-causing variants in his research.

Harnessing the Power of Ion AmpliSeq™ Exome Solution to Identify Disease-Causing Variants in your Research

Exome sequencing for every lab with the Ion AmpliSeq™ Exome Solution on the Ion Proton™ Sequencer

Proven to be a powerful tool for the identification of potentially disease-causing variants, exome sequencing is also a beneficial method for those studying germline mutations. However, workflow complexity and expense has kept many researchers from using this valuable approach. Now the new Ion AmpliSeq™ Exome Solution on the Ion Proton™ Sequencer provides an efficient and simple workflow.

Exome Sequencing in Today's Lab: Shifting the Paradigm in Translational and Clinical Research

In this webinar, the audience will learn about the current applications of exome sequencing in clinical research and its impact on the future of health care.

Total Transcriptome Analysis on the Ion Torrent™ Platform

Dr. Triche received his AB in physics and biology from Cornell University, an MD and PhD degree from Tulane University Medical Center, and his pathology training at Washington University Medical Center. He was the PI on both NCI Director's Challenge and SPECS grants to develop diagnostic and prognostic/predictive RNA expression profiles for childhood cancer, and co-founded GenomeDx, a company using similar technology to predict clinical recurrence of prostate cancer after prostatectomy. He is the Chair Emeritus of the pathology department at Children's Hospital Los Angeles and serves as Director of the Center for Personalized Medicine at CHLA, as well as co-Director of the Institute for Molecular Medicine, a collaborative effort between Phoenix Children's Hospital and TGen.

RNA Sequencing for Biomarker Discovery

Audrey Papp is a research specialist in Pharmacology with expertise in Pharmacogenomics and Molecular Pathology. As Technical Director of the Program in Pharmacogenomics at The Ohio State University, she is instrumental in developing new methods and approaches geared towards discovery of functional genetic biomarkers. She has played a leading role in implementation of Next Generation Sequencing in the Pharmacogenomics Core Laboratory. The Pharmacogenomics Core Lab is currently using both the Ion PGM™, and Ion Proton™ deep sequencing platforms.

Performing Transcriptome Sequencing on the Ion Proton™ System

Sequencing is a powerful tool for looking at the complexity of the transcriptome. This webinar will discuss considerations for preparing your transcriptome sequencing experiments along with the use of Life Technologies solutions including the Ion Proton™ System. Both upfront sample preparation from Ambion and downstream data analysis solutions from Partek will be described.

Ion AmpliSeq™ BRCA1 and BRCA2 Design Panels

These researchers, as part of the Life Technologies Consortium, use their expertise within specific disease research areas to create comprehensive, collaborative, and relevant gene panels featuring Ion AmpliSeq™ technology. Representing different international translational research institutions, these researchers bring many years of experience adopting the latest DNA sequencing and genotyping technologies to pioneering various disease research areas.